Dr. Konopleva on the Controversies Surrounding MRD in AML

By Marina Konopleva, MD, PhD, Chadi Nabhan, MD, MBA, FACP - Last Updated: September 8, 2023

Marina Konopleva, MD, PhD, of the Albert Einstein College of Medicine, joins Chadi Nabhan, MD, MBA, FACP, to discuss measurable residual disease (MRD) in acute myeloid leukemia (AML) at the Eleventh Annual Meeting of the Society of Hematologic Oncology.

Dr. Konopleva discusses the measurement and clinical utility of MRD, as well as what she sees on the horizon.

“I think it’s really controversial, but I think we are moving towards using that prognostically,” she said.

Dr. Konopleva explained why.

“Measurements remain controversial because of the complexity of AML,” she said. “I think the flow cytometry is still the best standardized assay, but the sensitivity is not where we would like it to be. But still, I think it’s the most accepted readout. With that said, it has to be done in a certified lab in a centralized fashion.”

She also spoke about highly sensitive tests for MRD in AML and what she sees as the “best example of MRD utility” in AML.

Post Tags:#SOHO 2023 Leukemia
Editorial Board